PHARMAC's funding of 9 weeks Herceptin: Many assumptions in a high-risk decision [5]

New Zealand Medical Journal

Volumn 120, Issue 1259, 2007, Pages

  Isaacs, Richard J ^a   Frampton, Christopher M ^b   Kuper Hommel, Marion J J ^a  

^a University of Otago ^*

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER MORTALITY; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; LETTER; MEDICAL DECISION MAKING; METHODOLOGY; NEW ZEALAND; OVERALL SURVIVAL; RESEARCH ETHICS; RESEARCH SUBJECT; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 36148978117     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Metcalfe S, Evans J, Priest G. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer NZMJ 120(1256). http://www.nzma.org.nz/journal/120-1256/2593
2. Perez EA, et al. Updated results of the combined analysis of NCCTG N9831 aA NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol (Meeting Abstracts). 2007;25:512.
3. Smith IE, et al. Two year follow up of trastuzumab after adjuvant chemotherapy in Her2 positive breast cancer: A randomised controlled trial. Lancet. 2007;369:29-36.
4. Slamon D, Eiermann W, Robert N, et al. Phase II Trial Comparing AC-T with AC-TH and with TCH in Adjuvant Treatment of HER2 positive Early Breast Cancer Patients: Second Interim Efficacy Analysis (Abstract). Presented at 29th Annual San Antonio Breast Cancer Symposium, December 2006.
5. Sledge GW, et al for ECOG. Adjuvant trastuzumab: Longterm results of E2198; SABCS proceedings; 2006, poster #2075.
6. Joensuu H, et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. N Engl J Med. 2006;354:809-20.
7. Early Breast Cancer Trialists' Collaborative Group. Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687-1717
8. Jönsson B, Wilking N. Market uptake of new oncology drug. Annals of Oncology. 2007;18(Supplement 3):iIi31-iii48.